RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has reaffirmed an Outperform rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $80 to $82.
January 12, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences and raises the price target from $80 to $82.
The increase in price target by RBC Capital suggests a positive outlook on the company's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100